Brian P. Bostick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Brian P. Bostick has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Adam Whaley-Connell
Department of Medicine–Endocrinology and Metabolism, University of Missouri School of Medicine, Columbia, Missouri, United States
2 shared publications- Anna M. Gonsalves
University of Missouri
2 shared publications - Brian Shariffi
University of Missouri
2 shared publications - Dain W. Jacob
University of Missouri
2 shared publications - Guanghong Jia
University of Missouri School of Medicine
2 shared publications - Guido Lastra
University of Missouri
2 shared publications
Latest Publications
- 1 July 2025
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 139 (1) , 239-248
Role of overweight and obesity on vascular responses to the cold pressor test and hypoxia in women
Sympathetic-mediated vasoconstriction is attenuated during hypoxia in young women with normal weight, demonstrating the expected hypoxic sympatholysis. Conversely, hypoxic sympatholysis is attenuated in women with increased adiposity, despite preserved sympathetic vasoconstriction and hypoxic vasodilation compared with women with normal weight. These data advance our understanding of the impact of obesity on neurovascular control of blood flow and have implications for individuals with obesity and conditions associated with hypoxia (e.g., sleep apnea).
- 1 July 2025
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 139 (1) , 239-248
Role of overweight and obesity on vascular responses to the cold pressor test and hypoxia in women
Sympathetic-mediated vasoconstriction is attenuated during hypoxia in young women with normal weight, demonstrating the expected hypoxic sympatholysis. Conversely, hypoxic sympatholysis is attenuated in women with increased adiposity, despite preserved sympathetic vasoconstriction and hypoxic vasodilation compared with women with normal weight. These data advance our understanding of the impact of obesity on neurovascular control of blood flow and have implications for individuals with obesity and conditions associated with hypoxia (e.g., sleep apnea).
- 1 July 2025
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 329 (1) , H233-H240
β-Adrenergic receptors mediate sex differences in vasodilation but not sympathetic-mediated vasoconstriction during hypoxia
β-Adrenergic receptors contribute to hypoxic vasodilation, attenuate sympathetic vasoconstriction at rest, and are more sensitive in females versus males. We hypothesized β-adrenergic receptor blockade would blunt hypoxic vasodilation and augment the sympathetic vasoconstriction during hypoxia, with effects greater in females relative to males. Present data demonstrate β-adrenergic receptors contribute to hypoxic vasodilation in females but do not restrain sympathetic-mediated vasoconstriction during hypoxia in either sex.
- 1 July 2025
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 329 (1) , H233-H240
β-Adrenergic receptors mediate sex differences in vasodilation but not sympathetic-mediated vasoconstriction during hypoxia
β-Adrenergic receptors contribute to hypoxic vasodilation, attenuate sympathetic vasoconstriction at rest, and are more sensitive in females versus males. We hypothesized β-adrenergic receptor blockade would blunt hypoxic vasodilation and augment the sympathetic vasoconstriction during hypoxia, with effects greater in females relative to males. Present data demonstrate β-adrenergic receptors contribute to hypoxic vasodilation in females but do not restrain sympathetic-mediated vasoconstriction during hypoxia in either sex.
- 1 October 2024
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 327 (4) , E533-E543
Enhanced ECCD36 signaling promotes skeletal muscle insulin resistance in female mice
ECCD36 exerts “extra endothelial cell” actions in skeletal muscle insulin resistance. ECCD36 is a major mediator of Western diet-induced lipid metabolic disorders and insulin resistance in skeletal muscle. Mitochondrial dysfunction is associated with diet-induced CD36 activation and related skeletal muscle insulin resistance.
- 1 October 2024
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 327 (4) , E533-E543
Enhanced ECCD36 signaling promotes skeletal muscle insulin resistance in female mice
ECCD36 exerts “extra endothelial cell” actions in skeletal muscle insulin resistance. ECCD36 is a major mediator of Western diet-induced lipid metabolic disorders and insulin resistance in skeletal muscle. Mitochondrial dysfunction is associated with diet-induced CD36 activation and related skeletal muscle insulin resistance.
- 1 September 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 327 (3) , F519-F531
The mineralocorticoid receptor in diabetic kidney disease
Diabetes mellitus is one of the leading causes of chronic kidney disease and its progression to end-stage kidney disease (ESKD). Diabetic kidney disease (DKD) is characterized by glomerular hypertrophy, hyperfiltration, inflammation, and the onset of albuminuria, together with a progressive reduction in glomerular filtration rate. This progression is further accompanied by tubulointerstitial inflammation and fibrosis. Factors such as genetic predisposition, epigenetic modifications, metabolic derangements, hemodynamic alterations, inflammation, and inappropriate renin-angiotensin-aldosterone system (RAAS) activity contribute to the onset and progression of DKD. In this context, decades of work have focused on glycemic and blood pressure reduction strategies, especially targeting the RAAS to slow disease progression. Although much of the work has focused on targeting angiotensin II, emerging data support that the mineralocorticoid receptor (MR) is integral in the development and progression of DKD. Molecular mechanisms linked to the underlying pathophysiological changes derived from MR activation include vascular endothelial and epithelial cell responses to oxidative stress and inflammation. These responses lead to alterations in the microcirculatory environment, the abnormal release of extracellular vesicles, gut dysbiosis, epithelial-mesenchymal transition, and kidney fibrosis. Herein, we present recent experimental and clinical evidence on the MR in DKD onset and progress along with new MR-based strategies for the treatment and prevention of DKD.
- 1 September 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 327 (3) , F519-F531
The mineralocorticoid receptor in diabetic kidney disease
Diabetes mellitus is one of the leading causes of chronic kidney disease and its progression to end-stage kidney disease (ESKD). Diabetic kidney disease (DKD) is characterized by glomerular hypertrophy, hyperfiltration, inflammation, and the onset of albuminuria, together with a progressive reduction in glomerular filtration rate. This progression is further accompanied by tubulointerstitial inflammation and fibrosis. Factors such as genetic predisposition, epigenetic modifications, metabolic derangements, hemodynamic alterations, inflammation, and inappropriate renin-angiotensin-aldosterone system (RAAS) activity contribute to the onset and progression of DKD. In this context, decades of work have focused on glycemic and blood pressure reduction strategies, especially targeting the RAAS to slow disease progression. Although much of the work has focused on targeting angiotensin II, emerging data support that the mineralocorticoid receptor (MR) is integral in the development and progression of DKD. Molecular mechanisms linked to the underlying pathophysiological changes derived from MR activation include vascular endothelial and epithelial cell responses to oxidative stress and inflammation. These responses lead to alterations in the microcirculatory environment, the abnormal release of extracellular vesicles, gut dysbiosis, epithelial-mesenchymal transition, and kidney fibrosis. Herein, we present recent experimental and clinical evidence on the MR in DKD onset and progress along with new MR-based strategies for the treatment and prevention of DKD.